Aura Biosciences Inc. (NASDAQ: AURA) completed enrollment of 108 patients in its Phase 3 CoMpass trial evaluating belzupacap sarotalocan as ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE